Search This Blog

Wednesday, November 30, 2022

Viridian at Evercore: Thyroid eye disease candidate

 Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company advancing new treatments for patients suffering from serious diseases underserved by current therapies, announced that senior management will participate in the 5th Annual Evercore ISI HealthCONx Conference on Thursday, December 1, 2022.

https://www.marketscreener.com/quote/stock/VIRIDIAN-THERAPEUTICS-IN-34091127/news/Viridian-Therapeutics-Inc-a-biotechnology-company-advancing-new-treatments-for-patients-suffering-42429454/


No comments:

Post a Comment

Note: Only a member of this blog may post a comment.